Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.58 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3105145 | 0.91 | SERPINE1 (0.59) | LMNASMN1; SMN2RXFP1CNR2 | |
| SCHEMBL14516827 | 0.90 | LMNA (0.59) | LMNASMN1; SMN2RXFP1CHRM1P2RX3 | |
| SCHEMBL5544822 | 0.90 | LMNA (0.73) | LMNASMN1; SMN2RXFP1CHRM1 | |
| SCHEMBL3234627 | 0.89 | TP53 (0.59) | LMNACHRM1CNR2TP53 | |
| SCHEMBL3238069 | 0.87 | LMNA (0.56) | LMNASMN1; SMN2RXFP1CHRM1CNR2 | |
| SCHEMBL3238407 | 0.87 | LMNA (0.55) | LMNACHRM1TP53 | |
| SCHEMBL1549051 | 0.86 | LMNA (0.81) | LMNACHRM1CNR2TP53 | |
| SCHEMBL2070531 | 0.86 | LMNA (0.71) | LMNACHRM1CNR2 | |
| SCHEMBL3234261 | 0.86 | LMNA (0.54) | LMNASMN1; SMN2RXFP1CHRM1P2RX3 | |
| SCHEMBL9028399 | 0.85 | LMNA (1.00) | LMNACHRM1CNR2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453846-B1 | 14 OR 15 MEMBERED MACROLIDES WITH ANTIBACTERIAL ACTIVITY | GLAXO GROUP LTD (GB) | 2007-05-16 | — | — | EP | disclosed |
| US-7202221-B2 | Macrolides | GLAXO GROUP LIMITED (GB) | 2007-04-10 | — | — | US | disclosed |
| US-20050080025-A1 | Macrolides | PLIVA D.D. (HR) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080025-A1 | Macrolides | IL17A, CYP51A1, IL15 | LMNA 1397/4885SMN1; SMN2 1568/4885RXFP1 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.